Bevacizumab (Bev) with or without erlotinib as maintenance therapy, following induction first-line chemotherapy plus Bev, in patients with metastatic colorectal cancer (mCRC): Efficacy and safety ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback